Inflammatory Disease Management During COVID-19 Pandemic

The management of chronic inflammatory diseases during the COVID-19 pandemic has presented unique clinical challenges for healthcare systems worldwide. Patients receiving immunosuppressive or immunomodulatory therapies have raised concerns regarding susceptibility to SARS-CoV-2 infection, disease severity and vaccine response. Clinicians have balanced the risk of halting disease-modifying treatments against potential viral complications, often with multidisciplinary input. Strategies have included risk stratification based on disease activity and comorbidities, minimising high-dose corticosteroids, and promoting vaccine uptake among vulnerable cohorts. The pandemic has accelerated adoption of telemedicine for monitoring and patient education, ensuring continuity of care while reducing exposure. Targeted interventions to mitigate cytokine release syndrome, such as selective interleukin or Janus kinase inhibitors, have emerged as promising approaches in severe COVID-19. This body of work highlights the global significance of optimising inflammatory disease therapy in the context of an evolving infectious threat, informing both pandemic preparedness and routine chronic disease management.

Research from Nature Portfolio

Recent studies have examined SARS-CoV-2 infection prevalence, outcomes and treatment implications in patients with chronic inflammatory skin disease. A cross-sectional survey of over 600 individuals with moderate-to-severe psoriasis reported an infection rate exceeding 80%, yet fewer than 6% required hospitalisation. Continuation of systemic therapies during infection did not increase COVID-19 severity, whereas treatment interruption was linked to disease flare. Booster vaccination reduced the likelihood of post-COVID-19 sequelae without compromising safety. These findings support the maintenance of specialist immunomodulatory regimens alongside vaccination to preserve disease control without elevating viral risk.

Inflammatory Disease Management During COVID-19 Pandemic publication trend

The graph below shows the total number of articles in inflammatory disease management during covid-19 pandemic across all publications each year (not limited to Nature Index journals).

Technical terms

Cytokine: A small protein released by immune cells that coordinates inflammation and immune responses.

Cytokine storm: An excessive, uncontrolled release of cytokines leading to widespread tissue inflammation and damage.

Immunomodulatory therapy: Treatment that alters the function or intensity of the immune system.

Biologic therapy: A class of medications derived from living organisms that target specific immune pathways.

Interleukin (IL): A subgroup of cytokines essential for communication between immune cells.

References

1. Prevalence, outcomes and associated factors of SARS-CoV-2 infection in psoriasis patients of Southwest China: a cross-sectional survey. Scientific Reports (2024).
2. Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19. Frontiers in Immunology (2023).
3. The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination. British Journal of Dermatology (2023).
4. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors. Journal of Dermatological Treatment (2022).